Hephaistos Pharma

Hephaistos is developing innate immunity modulators capable of transforming immuno-resistant ‘cold’ tumours into ‘hot’ tumours by modifying their micro-tumour environment. The company has obtained preclinical proof-of-concept for the first systemic TLR4 activator with efficacy against primary tumours and metastases, alone and in combination. The HEPHA-440 drug candidate has received orphan drug designation for the treatment of osteosarcoma and is expected to enter the clinic by 2027.